Whitney L Guerrero1, Gitonga Munene2, Paxton V Dickson1, Dina Darby3, Andrew M Davidoff4, Michael G Martin5, Evan S Glazer1, David Shibata1, Jeremiah L Deneve1. 1. Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Western Michigan University, Homer Stryker School of Medicine, West Michigan Cancer Center, Kalamazoo, MI, USA. 3. University of Tennessee Medical Practice, Surgical Oncology, Methodist Healthcare, Memphis, TN, USA. 4. Department of Pediatric Surgery, St Jude Children's Research Hospital, Memphis, TN, USA. 5. West Cancer Center, Memphis, TN, USA.
Abstract
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program. METHODS: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/HIPEC with clinicopathologic data described. RESULTS: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11-73 years). Primary pathology included: appendix (40%, n=20), ovary (20%, n=10), colon (14%, n=7), desmoplastic small round cell tumor (14%, n=7) or other (12%, n=6). The median peritoneal cancer index (PCI) score was 15.5 (range, 1-39) and 92% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 9.0 days (range, 6-35 days). Eight patients (16%) suffered major morbidity with 2 (4%) 30-day mortalities. CONCLUSIONS: Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal carcinomatosis (PC). We present our experience from a newly developed peritoneal surface malignancy program. METHODS: An IRB approved retrospective review was performed for the first 50 patients treated with CRS/HIPEC with clinicopathologic data described. RESULTS: Patients treated with CRS/HIPEC were Caucasian (64%), female (66%) with a median age of 53 years (range, 11-73 years). Primary pathology included: appendix (40%, n=20), ovary (20%, n=10), colon (14%, n=7), desmoplastic small round cell tumor (14%, n=7) or other (12%, n=6). The median peritoneal cancer index (PCI) score was 15.5 (range, 1-39) and 92% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 9.0 days (range, 6-35 days). Eight patients (16%) suffered major morbidity with 2 (4%) 30-day mortalities. CONCLUSIONS: Short-term outcomes observed after CRS/HIPEC in a newly developed center for PC are consistent with published higher volume center experiences.
Authors: Chelsea C Pinnix; Hiral P Fontanilla; Andrea Hayes-Jordan; Vivek Subbiah; Stephen D Bilton; Eric L Chang; David R Grosshans; Mary F McAleer; Eric P Sulman; Shiao Y Woo; Peter Anderson; Holly L Green; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: S Kusamura; B J Moran; P H Sugarbaker; E A Levine; D Elias; D Baratti; D L Morris; A Sardi; O Glehen; M Deraco Journal: Br J Surg Date: 2014-10-20 Impact factor: 6.939
Authors: Shuja Ahmed; Edward A Levine; Reese W Randle; Katrina R Swett; Perry Shen; John H Stewart; Konstantinos I Votanopoulos Journal: Ann Surg Oncol Date: 2014-07-18 Impact factor: 5.344
Authors: Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos Journal: J Am Coll Surg Date: 2013-12-21 Impact factor: 6.113
Authors: Paul H Sugarbaker; Robert Alderman; Gary Edwards; Christina Ellen Marquardt; Vadim Gushchin; Jesus Esquivel; David Chang Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Thejus T Jayakrishnan; Anthony J Zacharias; Avishkar Sharma; Sam G Pappas; T Clark Gamblin; Kiran K Turaga Journal: World J Surg Oncol Date: 2014-08-21 Impact factor: 2.754